Desmopressin Acetate for Injection
Vials：1ml：xxμg / 1ml：xxμg
Indications and Usage:
A. Shortening or normalisation of prolonged bleeding time prior to an invasive therapeutic or diagnostic operation, or for therapeutic control of bleeding in patients with prolonged bleeding time as a consequence of congenital or substance-
B. For the therapeutic control of bleeding and bleeding prophylaxis in connection with minor surgical procedures in patients with mild haemophilia A and von Willebrand’s disease who respond positively to a test dose. In exceptional cases, even moderate forms of the disease can be treated. MINIRIN must not be used in patients with von Willebrand’s disease type IIB.
C. Treatment of central diabetes insipidus and for establishing renal concentration capacity testing.
A. For the dose upon 0.x µg/kg body weight, diluted in physiological saline to 50-
Determine the coagulation factors and bleeding time before desmopressin treatment. Plasma levels of VIII:C and vWF:Ag increase substantially after desmopressin administration. However, it has not been possible to establish any correlation between the plasma concentration of these factors and the bleeding time, either before or after desmopressin. The effect of desmopressin on the bleeding time should therefore, if possible, be tested in the individual patient. The bleeding time test should be as standardised as possible, e.g. with the use of Simplate II. Determination of bleeding time and plasma levels of the coagulation factors should be conducted in co-
B. Central diabetes insipidus
If the intranasal presentation is not available, desmopressin acetate for injection can be used. Dose adjusted according to patient’s urine volume and urine osmotic pressure.
Normal dose by intramuscular injection: Adults x-
C. Kidney urine concentration test
Normal dose by intramuscular or subcutaneous injection: Adults 4µg (1ml), for children above the age of 1 year, x-